[{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Genetika

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aims to advance clinical development of PrimeC (ciprofloxacin and celecoxib), currently in mid-stage trials for Alzheimer's disease.

                          Brand Name : PrimeC

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : Ciprofloxacin,Celecoxib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : NeuroSense Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank